glp-1 shortage news today november 2025 trends 2025: real-world data, patient outcomes & future therapies ISPOR 2025: Exploring reasons for

reimbursed chronic disease), GLP-1 stakeholders must recalibrate go-to-market models by balancing reimbursement strategy, innovation, brand equity and execution speed before competition closes the window

Eaglenos is working on lactate

Briyal S, Shah S, Gulati A (2014) Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia

Second, SGLT2 inhibitors were shown to have the greatest cardiovascular and all-cause mortality benefits amongst all three new antidiabetic drug classes

In animal studies, GLP1-agonists were associated with reduced fetal weight and/or growth, delayed ossification and skeletal variants, usually associated with a reduction in maternal weight gain and decreased food consumption